Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/4/2026

1. NKE
2. USO
3. SPY
4. ACN
5. NVDA
6. FICO
7. TRU
8. TLT
9. LAES
10. WBD

Go back to Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)
(NASDAQ: KPRX) Delayed: 2.56 -0.02 (0.78%)
Previous Close $2.58    52 Week High $ 
Open $2.55    52 Week Low $ 
Day High $2.56    P/E N/A 
Day Low $2.55    EPS $ 
Volume 3,437